Shareholders Approve Stock Incentive Plan, Authorizing 34% Potential Dilution

summarizeSummary

Inmune Bio shareholders approved an expanded stock incentive plan, potentially diluting existing shareholders by over 34% initially, with further annual dilution authorized through an evergreen provision.

check_boxKey Events

• Expanded Stock Incentive Plan Approved

  Shareholders approved the Third Amended and Restated 2021 Stock Incentive Plan, increasing the shares reserved for awards from 6.5 million to 9,158,525 shares.

• Significant Potential Dilution

  The 9,158,525 shares authorized for the plan represent a potential dilution of approximately 34.45% based on the 26,585,258 shares outstanding as of the April 20, 2026 record date.

• Evergreen Provision for Future Dilution

  An evergreen provision was approved, allowing for automatic annual increases of up to 10.0% of outstanding shares from 2027 through 2031, adding to long-term dilution potential.

• Routine Shareholder Matters

  Stockholders also re-elected five directors and ratified the appointment of CBIZ CPAs P.C. as the independent auditor for 2026.

auto_awesomeAnalysis

Shareholders approved a significantly expanded stock incentive plan, increasing the total shares reserved for awards to 9.16 million. This represents a potential dilution of approximately 34.45% based on the 26.59 million shares outstanding at the record date. Additionally, an evergreen provision was approved, allowing for annual increases of up to 10% of outstanding shares from 2027 through 2031, which will lead to further substantial dilution over time. While incentive plans are crucial for attracting and retaining talent in a life sciences company, especially following recent positive FDA and clinical trial news, the magnitude of this potential dilution is a significant negative for existing shareholders, particularly given the company's reiterated 'going concern' warning.